Skip to main content

Live Webinar

RAPS Sponsored Webcast: Plain Language Summaries: Understanding the “Why” Behind the Regulations and Guidance

Register now

Wednesday, October 18, 2023 11am (ET)

TECH-ENABLED SERVICES

Unmatched Experience and Expertise

Our drug-development consultation services reflect decades of experience from more than 650 healthcare and pharmaceutical professionals, as well as leading-edge technological solutions. This combination delivers the insights and knowledge to accelerate regulatory and commercial success while saving time and money.  Over the last decade, we have worked on more than 7,000 customer projects, across practice areas and drug development phases, leading to the extensive experience our customers highly value.

EXPLORE SERVICES

PROPRIETARY SOFTWARE

Leading the Industry in Drug Discovery and Development

Our quantitative approach to model-informed drug development offers a comprehensive view of the clinical and regulatory possibilities and challenges facing new therapies.  We derive significant insights that inform the development of our biosimulation software. These insights help us to anticipate and align our technology roadmap with our customers’ needs and priorities.  By providing the clearest picture of both opportunities and risks in the development lifecycle, we remove doubt and inspire confidence at key milestones during the process.

BROWSE SOFTWARE

Pinnacle 21 Regulatory CDISC Compliance Software

Pinnacle 21 Regulatory CDISC Compliance Software

The data management and compliance solution for data needs: speccing, mapping, cleaning, checking, comparing, transforming, converting.

Learn More
Phoenix Pharmacokinetic / Pharmacodynamic Platform

Phoenix Pharmacokinetic / Pharmacodynamic Platform

The global leader in software for preparing clinical trial data for regulatory submission.

Learn More
Simcyp Physiologically Based Pharmacokinetic (PBPK)

Simcyp Physiologically Based Pharmacokinetic (PBPK)

Simcyp PBPK models describe the behavior of drugs in different body tissues, with each tissue considered a physiological compartment.

Learn More
D360 Scientific Informatics Platform

D360 Scientific Informatics Platform

The platform, used by over 6,000 discovery scientists for small molecule and biologics research, provides self-service data access and integrated analysis solution.

Learn More
Certara.AI Platform

Certara.AI Platform

Certara.AI allows you to solve data silo problems while improving analytics capabilities that drive productivity and accelerated data discovery across life science R&D.

Learn More

SCIENTIFIC CONTENT

Transforming the Future of Drug Development

Our goal is to not only push the boundaries of what’s possible through medical therapies and devices, but also to challenge the thinking that drives regulatory science. We are committed to sharing our thought leaders’ insights and findings to question current approaches and envision what the future holds for biosimulation and public health.

VIEW MORE

01

Learn how Certara’s Integral streamlines PK/PD workflows & ensures compliance with regulatory requirements

PK/PD data comes from multiple sources, making it challenging to efficiently search, visualize, and analyze your data, and remain compliant for regulatory submissions. Especially with the large volumes of PK/PD data required for today’s complex clinical trials. With Certara’s Integral data and model repository, you’ll streamline your PK/PD workflows and ensure compliance with regulatory requirements &hellip; <a href="https://www.certara.com/webinar/october-learn-how-certaras-integral-streamlines-pk-pd-workflows-amp-ensures-compliance-with-regulatory-requirements/">Continued</a>

Read More

01

ICER’s Unsupported Price Increase Report: Unfit for Policymaking

Since 2019, the Institute for Clinical and Economic Review (ICER) has published an annual Unsupported Price Increase (UPI) Report on its “assessment on drugs that experience significant price hikes without any novel clinical evidence” to guide policy making on prescription drugs. US lawmakers have shown interest in the UPI approach as a potential tool to … Continued

Read More

01

Maximizing Reusability for Drug Submissions to Different Health Authorities

Many drug developers have products that they want to submit for marketing approval in several regions like the US (NDA/BLA), Europe (MAA (Marketing Authorization Applications)), Canada (NDS (New Drug Submissions)), and elsewhere. But developing each submission independently can waste a lot of time and money. Fortunately, there are ways to maximize the reusability of your … Continued

Read More

Your Trusted Partner for Key Decision Points

“Certara’s contribution to the drug development program for Nurtec ODT was substantial. Their clinical pharmacology representative worked seamlessly with the Biohaven Development Team. Certara’s considerable expertise in clinical pharmacology and pharmacometrics and flawless execution supported Nurtec’s clinical development team and helped to prepare the clinical pharmacology NDA components.” Richard Bertz, PhDVice President, Clinical Pharmacology & Pharmacometrics

01

How A Biotech Startup Company Increased Flexibility and Efficiency by Switching to Phoenix Hosted
Read More

FEATURED CASE STUDIES

Success is Achieved Together

Biosimulation can reduce the size of and cost of human trials, the most expensive and time-consuming part of drug development.  In some cases, we can eliminate certain human trials completely.   More than 2,000 customers worldwide choose us as their partner for biosimulation software and technology-driven services. See how we have helped companies like yours redefine what’s possible for safe and effective modern medicine.

Visit Case Studies